SCHEMBL207581

SCHEMBL207581

Cc1cccc(CNC(=O)CCC(=O)NC2CCC(Cc3cccc(Cl)c3)(N(C)C)CC2)c1

nearest known ligand 0.46

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
POLB P06746 1/20 0.46
EPHX2 P34913 1/20 0.44
THRB P10828 2/20 0.44
HPGD P15428 1/20 0.44
NR1H4 Q96RI1 2/20 0.43
MAPT P10636 3/20 0.42
ALOX12 P18054 1/20 0.42
SSTR1 P30872 1/20 0.41
SSTR4 P31391 1/20 0.41
TP53 P04637 2/20 0.41
CXCR4 P61073 1/20 0.41
SIGMAR1 Q99720 1/20 0.40
RXFP1 Q9HBX9 1/20 0.40
CYP3A4 P08684 1/20 0.40
CYP2C9 P11712 1/20 0.40
CYP2C19 P33261 1/20 0.40
P2RX7 Q99572 1/20 0.40
KMT2A Q03164 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL206772 0.92 EPHX2 (0.47) POLBEPHX2THRBHPGDMAPT
SCHEMBL206288 0.91 ALDH1A1 (0.50) EPHX2THRBHPGDMAPTTP53
SCHEMBL206620 0.91 EPHX2 (0.46) POLBEPHX2THRBHPGDNR1H4
SCHEMBL206685 0.90 EPHX2 (0.43) POLBEPHX2THRBHPGDMAPT
SCHEMBL206579 0.90 TRPV1 (0.44) POLBEPHX2THRBHPGDMAPT
SCHEMBL206617 0.89 SIGMAR1 (0.43) POLBEPHX2THRBHPGDMAPT
SCHEMBL206643 0.89 SSTR4 (0.43) NR1H4SSTR1SSTR4SIGMAR1CYP2C9
SCHEMBL208251 0.88 SIGMAR1 (0.42) POLBEPHX2THRBHPGDMAPT
SCHEMBL206014 0.88 SIGMAR1 (0.43) POLBEPHX2THRBHPGDMAPT
SCHEMBL205370 0.88 SIGMAR1 (0.50) POLBEPHX2THRBHPGDTP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8088763-B2 e.g. N-[1-(2,6-dichloro-benzyl)-pyrrolidin-3-yl]-N'-[4-dimethylamino-4-(4-methyl-benzyl)-cyclohexyl]-succinamide; noradrenaline and serotonin reuptake ihibitor; opioid ORL-1 receptor ligand; analgesic, antidepressant, anxiolytic agent, neurodegenerative diseases GRUENENTHAL GMBH (DE) 2012-01-03 US claimed
EP-1745010-B1 SUBSTITUTED CYCLOHEXYL-1,4-DIAMINE DERIVATIVES GRUENENTHAL GMBH (DE) 2009-08-05 EP claimed
US-20070112007-A1 Cyclohexyl-1, 4-diamine compounds GRUENENTHAL GMBH (DE) 2007-05-17 US claimed
US-8088763-B2 e.g. N-[1-(2,6-dichloro-benzyl)-pyrrolidin-3-yl]-N'-[4-dimethylamino-4-(4-methyl-benzyl)-cyclohexyl]-succinamide; noradrenaline and serotonin reuptake ihibitor; opioid ORL-1 receptor ligand; analgesic, antidepressant, anxiolytic agent, neurodegenerative diseases GRUENENTHAL GMBH (DE) 2012-01-03 US disclosed
EP-1745010-B1 SUBSTITUTED CYCLOHEXYL-1,4-DIAMINE DERIVATIVES GRUENENTHAL GMBH (DE) 2009-08-05 EP disclosed
US-20070112007-A1 Cyclohexyl-1, 4-diamine compounds GRUENENTHAL GMBH (DE) 2007-05-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070112007-A1 Cyclohexyl-1, 4-diamine compounds PKD1, DDC, DPYD POLB 1568/4885EPHX2 1203/4885THRB 4068/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.